 Myovant Sciences NYSE: MYOV and Pfizer NYSE: PFE announced an update for an sNDA for MYFEMBREE, which is designed to manage severe to moderate pain linked to endometriosis. According to the ongoing review of this new application, the FDA provided notice that it had identified some deficiencies that preclude talks of post-marketing andor labeling requirements. 